<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21559284</article-id><article-id pub-id-type="pmc">3086909</article-id><article-id pub-id-type="publisher-id">PONE-D-11-00898</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0019392</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic Endocrinology</subject><subj-group><subject>Diabetes Mellitus Type 2</subject></subj-group></subj-group><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject></subj-group></subj-group><subj-group><subject>Pituitary</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Insulin and GH Signaling in Human Skeletal Muscle <italic>In
Vivo</italic> following Exogenous GH Exposure: Impact of an Oral Glucose
Load</article-title><alt-title alt-title-type="running-head">Insulin and GH Signaling in Skeletal
Muscle</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krusenstjerna-Hafstr&#x000f8;m</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Madsen</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vendelbo</surname><given-names>Mikkel H.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Steen B.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Christiansen</surname><given-names>Jens S.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000f8;ller</surname><given-names>Niels</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jessen</surname><given-names>Niels</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>Jens O. L.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Internal Medicine and Endocrinology (MEA) and Medical
Research Laboratories, Aarhus University Hospital, Aarhus, Denmark</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus,
Denmark</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Fadini</surname><given-names>Gian Paolo</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Padova, Medical School, Italy</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>tk-h@ki.au.dk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: TK-H MM MHV NM JSC NJ JOLJ. Performed
the experiments: TK-H MHV. Analyzed the data: TK-H MM MHV SBP NM NJ JOLJ.
Contributed reagents/materials/analysis tools: SBP NJ JSC. Wrote the paper:
TK-H MM MHV SBP JSC NM NJ JOLJ.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>3</day><month>5</month><year>2011</year></pub-date><volume>6</volume><issue>5</issue><elocation-id>e19392</elocation-id><history><date date-type="received"><day>3</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2011</year></date></history><permissions><copyright-statement>Krusenstjerna-Hafstr&#x000f8;m et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>GH induces acute insulin resistance in skeletal muscle in vivo, which in
rodent models has been attributed to crosstalk between GH and insulin
signaling pathways. Our objective was to characterize time course changes in
signaling pathways for GH and insulin in human skeletal muscle in vivo
following GH exposure in the presence and absence of an oral glucose
load.</p></sec><sec><title>Methods</title><p>Eight young men were studied in a single-blinded randomized crossover design
on 3 occasions: 1) after an intravenous GH bolus 2) after an intravenous GH
bolus plus an oral glucose load (OGTT), and 3) after intravenous saline plus
OGTT. Muscle biopsies were taken at t&#x0200a;=&#x0200a;0, 30, 60, and
120. Blood was sampled at frequent intervals for assessment of GH, insulin,
glucose, and free fatty acids (FFA).</p></sec><sec><title>Results</title><p>GH increased AUC<sub>glucose</sub> after an OGTT (p&#x0003c;0.05) without
significant changes in serum insulin levels. GH induced phosphorylation of
STAT5 independently of the OGTT. Conversely, the OGTT induced acute
phosphorylation of the insulin signaling proteins Akt (ser<sup>473</sup> and
thr<sup>308</sup>), and AS160.The combination of OGTT and GH suppressed
Akt activation, whereas the downstream expression of AS160 was amplified by
GH.</p></sec><sec><title>We Concluded the Following</title><p>1) A physiological GH bolus activates STAT5 signaling pathways in skeletal
muscle irrespective of ambient glucose and insulin levels 2) Insulin
resistance induced by GH occurs without a distinct suppression of insulin
signaling proteins 3) The accentuation of the glucose-stimulated activation
of AS 160 by GH does however indicate a potential crosstalk between insulin
and GH.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00477997">NCT00477997</ext-link>
</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Growth hormone (GH) promotes longitudinal growth and somatic maturation in children
and adolescents and is also an important regulator of substrate metabolism and
insulin sensitivity <xref rid="pone.0019392-Moller1" ref-type="bibr">[1]</xref>. In the post-absorptive phase, where endogenous GH
secretion is stimulated, GH promotes lipolysis and oxidation of fatty acids at the
expense of glucose <xref rid="pone.0019392-Moller2" ref-type="bibr">[2]</xref>,<xref rid="pone.0019392-Moller3" ref-type="bibr">[3]</xref>. This insulin-antagonistic effect is accentuated during
more prolonged fasting and may constitute a favorable protein-saving mechanism due
to impeded demand for gluconeogenesis from amino acids <xref rid="pone.0019392-Norrelund1" ref-type="bibr">[4]</xref>&#x02013;<xref rid="pone.0019392-Norrelund3" ref-type="bibr">[6]</xref>. On the other hand, sustained
GH elevations in non-fasting conditions, as seen in acromegaly, may result in
glucose intolerance, and manifest diabetes mellitus <xref rid="pone.0019392-Moller4" ref-type="bibr">[7]</xref>,<xref rid="pone.0019392-Sonksen1" ref-type="bibr">[8]</xref>.</p><p>The molecular mechanisms by which GH causes insulin resistance are unclear.
Insulin-stimulated glucose transport into skeletal muscle depends on the activation
of a signaling cascade involving insulin receptor substrate 1 (IRS-1), the
phosphatidylinositol 3-kinase, Akt, and Akt substrate of 160&#x02005;kDa (AS160)
<xref rid="pone.0019392-Sakamoto1" ref-type="bibr">[9]</xref>. The
entirety of the signaling cascade is not yet known and may include additional
proteins. However, it is well known that insulin signaling ultimately promotes
translocation of the glucose transporter GLUT4 to the cell surface. Any step in this
cascade is a potential target for GH, and could involve direct crosstalk between
signaling proteins, or indirect effects via free fatty acids (FFA), a known
inhibitor of insulin receptor signaling in human skeletal muscle <xref rid="pone.0019392-Shulman1" ref-type="bibr">[10]</xref>.</p><p>The predominant GH signaling cascade comprises activation of the GHR dimer,
phosphorylation of JAK2 and subsequently of STAT5 <xref rid="pone.0019392-Lanning1" ref-type="bibr">[11]</xref>, but there is also animal and
<italic>in vitro</italic> evidence to suggest that insulin and GH share
post-receptor signaling pathways <xref rid="pone.0019392-Dominici1" ref-type="bibr">[12]</xref>. However, a cross-talk between GH and insulin signaling
pathways has not been confirmed in human models <italic>in vivo</italic>
<xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>,<xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>. This may,
however, relate to the design of these studies. First, signaling was assessed in
either the basal state, where insulin activity is minimal <xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>, or during a euglycemic
hyperinsulinemic glucose clamp <xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>, which is an unphysiological condition. Second, only
single biopsies were obtained in both studies, which may be insufficient because of
the rapid and fluctuating nature of the post receptor signaling cascades. Third,
measurement of signaling proteins downstream of Akt has so far not been performed.
It should also be noted that human <italic>in vivo</italic> data on the time course
of stimulated insulin signaling pathways after an oral glucose tolerance load have
not previously been reported.</p><p>We therefore conducted a study where temporal changes in the activation of signaling
proteins downstream of the receptors for GH and insulin were assessed in serial
muscle biopsies in healthy human subjects following a physiological GH bolus with
and without a concomitant oral glucose load (OGTT).</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study Protocol And Informed Consent</title><p>The study protocol was approved by The Regional Scientific Ethics Committee of
Denmark (M-20070052) and all participants gave oral and written informed consent
to participate. The study was conducted in accordance to the Helsinki
Declaration.</p></sec><sec id="s2b"><title>Subjects</title><p>We studied 8 healthy men aged 24.6&#x000b1;1.8 year (mean &#x000b1; SE) with a mean
body mass index of 24.2&#x000b1;1.2&#x02005;kgxm<sup>&#x02212;2</sup> in a
randomized, crossover design. Routine blood chemistry including fasting blood
glucose and HbA1c levels were normal in all participants, none of whom received
any medication.</p></sec><sec id="s2c"><title>Study Design</title><p>Each participant was studied on 3 separate occasions in a randomized fashion
(<xref ref-type="fig" rid="pone-0019392-g001">Figure 1</xref>): 1) after an
intravenous GH bolus (0.5&#x02005;mg Genotropin, Miniquick, Pfizer, Inc.)(GH); 2)
after a blinded intravenous GH bolus (0.5&#x02005;mg) plus an oral glucose load
(75&#x02005;g) (GH &#x0002b; OGTT); and 3) after a blinded intravenous saline bolus
plus an oral glucose load (OGTT). At least two weeks elapsed between each study,
which was performed after an overnight fast for 12&#x02005;hours and with the
participants resting in the supine position.</p><fig id="pone-0019392-g001" position="float"><label>Figure 1</label><caption><title>Study design.</title><p>Please refer to the paragraph <italic>study design</italic> for further
details.</p></caption><graphic xlink:href="pone.0019392.g001"/></fig><p>A catheter was inserted in an antecubital vein in each arm, one for
administration of GH/saline, and one for blood sampling. At 09.00&#x02005;h
(t&#x0200a;=&#x0200a;0&#x02005;min) the participants received GH/saline
&#x000b1;OGTT. Muscle biopsies were obtained at
t&#x0200a;=&#x0200a;0&#x02005;min (just before the intervention),
t&#x0200a;=&#x0200a;30&#x02005;min, t&#x0200a;=&#x0200a;60&#x02005;min,
t&#x0200a;=&#x0200a;120&#x02005;min. The biopsies were taken from the vastus
lateralis muscle with a Bergstr&#x000f6;m biopsy needle under local anesthesia
(1&#x00025; lidocain); a small incision was made through the skin and muscle
sheath 15&#x02013;20&#x02005;cm above the knee. The biopsies were taken in random
order two by two, meaning that the first (t&#x0200a;=&#x0200a;0&#x02005;min)
and the second (t&#x0200a;=&#x0200a;30&#x02005;min) were taken from the same
thigh, and the third (t&#x0200a;=&#x0200a;60&#x02005;min) and the fourth
(t&#x0200a;=&#x0200a;120&#x02005;min) from the contra lateral thigh. A total
amount of &#x02248;150&#x02005;mg of muscle was obtained per biopsy. The tissue was
cleansed from blood (within 10&#x02005;sec) and snap-frozen in liquid nitrogen.
Muscle biopsies were stored at &#x02212;80&#x000b0;C until analyzed. Blood was
collected just before the first biopsy (t&#x0200a;=&#x0200a;0), five min
after (t&#x0200a;=&#x0200a;5), and every 10&#x02005;min within the first
hour (t&#x0200a;=&#x0200a;10, 20, 30, 40, 50, 60). After the first hour
blood was collected every 30&#x02005;min until one hour after the last biopsy
(t&#x0200a;=&#x0200a;90, 120, 150, 180). Plasma glucose and serum GH were
measured at every time point. FFA was measured every 20&#x02005;min within the
first hour (t&#x0200a;=&#x0200a;0, 20, 40, 60) and every 30&#x02005;min
afterwards (t&#x0200a;=&#x0200a;90,120,150,180). Serum insulin was measured
at 0, 20, 30, 40, 60, 120, 180&#x02005;min. Body composition and aerobic exercise
capacity (VO2-max) were assessed after completion of the study by Dual-emission
X-ray absorptiometry and a bicycle ergometer, respectively.</p></sec><sec id="s2d"><title>Hormones And Metabolites</title><p>Plasma glucose was measured immediately in duplicates on two Beckman
Glucoanalyzers (Beckman Instruments, Palo Alto, CA). Serum insulin and GH were
measured using time-resolved fluoroimmunoassays (TF-IFMA; AutoDELFIA,
PerkinElmer, Turku, Finland), FFA was analyzed by a colorimetric method using a
commercial kit (Wako Chemicals, Neuss, Germany).</p></sec><sec id="s2e"><title>Intracellular Signal Transduction</title><p>Muscle biopsies were homogenized as previously described <xref rid="pone.0019392-Wojtaszewski1" ref-type="bibr">[15]</xref>.</p><p>
<italic>Western blot</italic>: Aliquots of protein were resolved by SDS-PAGE, and
proteins were transferred onto nitrocellulose membranes. Immunoblotting was
performed using primary antibodies as follows: phosho-STAT5, STAT5, phosho Akt,
Akt2, phospho-P38, P38, phosho-Akt substrate (PAS), and Akt substrate 160
(AS160), all obtained from Cell Signaling (Beverly, MA). Membranes were
incubated with horseradish peroxidase&#x02013;coupled secondary antibodies,
visualized by BioWest enhanced chemiluminescence (UVP LabWorks, Upland, CA) and
quantified by the UVP BioImaging System.</p><p>Membranes probed with the phospho-specific antibodies were stripped in a buffer
containing 100&#x02005;mmolxl<sup>&#x02212;1</sup> 2-mercaptoethanol,
0.02&#x02005;gxml<sup>&#x02212;1</sup> SDS and
62.5&#x02005;mmolxl<sup>&#x02212;1</sup> Tris&#x02013;HCl (pH&#x02005;6.7), and
re-probed with corresponding total antibody. The signal from the
phospho-specific antibodies was related to total protein expression in the
sample. STAT5 protein bands were identified using human muscle stimulated with
GH as positive controls <xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>.The remaining bands were identified using insulin
stimulated rat muscle <xref rid="pone.0019392-Jessen1" ref-type="bibr">[16]</xref>. Phosphorylation of AS160 was identified as insulin
responsive band at approximately 160&#x02005;kDa using the phospho-Akt substrate
(PAS) antibody (Cell Signaling). This antibody has been shown to primarily
identify AS160 in human skeletal muscle <xref rid="pone.0019392-Treebak1" ref-type="bibr">[17]</xref>,<xref rid="pone.0019392-Hojlund1" ref-type="bibr">[18]</xref> but a potential
cross-reaction with the AS160 paralogue TBC1D1 (&#x0223c;155&#x02005;kDa) cannot be
completely excluded.</p></sec><sec id="s2f"><title>Isolation Of Rna</title><p>Skeletal muscle (20&#x02005;mg) was homogenized in TriZol reagent (Gibco BRL, Life
Technologies, Roskilde, Denmark). RNA was quantitated by measuring absorbency at
260&#x02005;nm and 280&#x02005;nm and the Integrity of the RNA was checked by
visual inspection of the two ribosomal RNAs on an ethidium bromide stained
agarose gel.</p></sec><sec id="s2g"><title>Real-Time Rt-Pcr For Mrna Analysis</title><p>Reverse transcription was performed using random hexamer primers as described by
the manufacturer (GeneAmp RNA PCR Kit from Perkin Elmer Cetus, Norwalk, CT).
Then, PCR-mastermix containing the specific primers and Taq DNA polymerase
(HotStar Taq, Quiagen Inc. USA) were added. The following primers were designed
using the primer analysis software Oligo version 6.64:</p><p>IGF1: <named-content content-type="gene">5&#x02032;GACAGGGGCTTTTATTTCAAC
3&#x02032;</named-content>and <named-content content-type="gene">5&#x02032;
CTCCAGCCTCCTTAGATCAC 3&#x02032;</named-content>, 117&#x02005;bp, SOCS1:
<named-content content-type="gene">5&#x02032;ACACGCACTTCCGCACATTC
3&#x02032;</named-content>and <named-content content-type="gene">5&#x02032;
CGAGGCCATCTTCACGCTAAG 3&#x02032;</named-content>, 209&#x02005;bp; SOCS2:
<named-content content-type="gene">5&#x02032;GGTCGAGGCGATCAGTG
3&#x02032;</named-content>and <named-content content-type="gene">5&#x02032;
TCCTTGAAGTCAGTGCGAATC 3&#x02032;</named-content>, 209&#x02005;bp; SOCS3:
<named-content content-type="gene">5&#x02032;CGGCCACTTGGACTCTGA
3&#x02032;</named-content>and <named-content content-type="gene">5&#x02032;
GCCCTTTGCGCCCTTT 3&#x02032;</named-content>, 106&#x02005;bp; &#x003b2;-actin
<named-content content-type="gene">5&#x02032; ACGGGGTCACCCACACTGTGC
3&#x02032;</named-content> and <named-content content-type="gene">5&#x02032;
CTAGAAGCATTTGCGGTGGACGATG 3&#x02032;</named-content>, 658&#x02005;bp. Real time
quantization of target gene to &#x000df;-actin mRNA was performed with a
SYBR-Green real-time PCR assay using an ICycler from BioRad. The threshold cycle
(Ct) was calculated, and the relative gene-expression was calculated essentially
as described in the User Bulletin #2, 1997 from Perkin Elmer (Perkin Elmer
Cetus, Norwalk, CT).</p></sec><sec id="s2h"><title>Statistics</title><p>Data are presented as means &#x000b1; SE when normally distributed, and median
(ranges) (25&#x00025;; 75&#x00025;) when not. Statistical evaluation of
differences between normally distributed data was performed with a paired
<italic>t</italic>-test and with Wilcoxon rank sum test when data were not
normally distributed. Time series of serum measurements and results from Western
blots were analyzed by ANOVA for repeated measurements or by using area under
curve (AUC). Correlation analyses were performed using Person's correlation
coefficient. A p value&#x0003c;0.05 was considered statistical significant.
Statistical analysis was performed using SPSS version 17.0 for windows (SPSS,
Chicago, IL).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Glucose</title><p>A significant difference between the plasma glucose curves obtained from
OGTT&#x0002b;GH vs. OGTT alone was recorded (ANOVA, p&#x0200a;=&#x0200a;0.04)
(<xref ref-type="fig" rid="pone-0019392-g002">Figure 2a</xref>). There also
was a statistical significant difference in AUC<sub>glucose</sub>
((mmolxl<sup>&#x02212;1</sup>xmin<sup>&#x02212;1</sup>) [1200&#x000b1;41
(OGTT&#x0002b;GH) vs. 1105&#x000b1;35 (OGTT) (p&#x0200a;=&#x0200a;0.04) (<xref ref-type="fig" rid="pone-0019392-g002">Figure 2b</xref>)]. Moreover, GH
together with an OGTT tended to increase peak levels of plasma glucose
(C<sub>max</sub>) (p&#x0200a;=&#x0200a;0.06) compared to OGTT alone
(<xref ref-type="fig" rid="pone-0019392-g002">Figure 2a</xref>).</p><fig id="pone-0019392-g002" position="float"><label>Figure 2</label><caption><title>Glucose measurements.</title><p>(A) Plasma levels of glucose. OGTT, oral glucose tolerance test
(75&#x02005;g glucose). GH, growth hormone bolus (0.5&#x02005;mg). Black
circles&#x0200a;=&#x0200a;OGTT &#x0002b; GH, white
circles&#x0200a;=&#x0200a;OGTT, black
triangles&#x0200a;=&#x0200a;GH. Data are presented as mean &#x000b1;
SE. Using ANOVA repeated measurements showed a significant difference
between OGTT and OGTT&#x0002b;GH (p&#x0200a;=&#x0200a;4) (B)
AUC-glucose, area under glucose curve. P-value is based on paired t-test
between area under curve for OGTT and area under curve for OGTT&#x0002b;GH.
Data are presented as mean &#x000b1; SE. There was a significant
difference in AUC-glucose between OGTT and OGTT&#x0002b;GH
(p&#x0200a;=&#x0200a;0.04).</p></caption><graphic xlink:href="pone.0019392.g002"/></fig></sec><sec id="s3b"><title>Insulin, Gh, And Ffa</title><p>Baseline and glucose-stimulated insulin levels (pmolxl<sup>&#x02212;1</sup>) were
not significantly influenced by concomitant GH exposure [C<sub>max</sub>:
281&#x000b1;57 (OGTT) vs. 243&#x000b1;33 (OGTT&#x0002b;GH)
(p&#x0200a;=&#x0200a;0.39); T<sub>max</sub> (min): 49&#x000b1;11 (OGTT) vs.
61&#x000b1;14 (OGTT&#x0002b;GH) (p&#x0200a;=&#x0200a;0.57) (<xref ref-type="fig" rid="pone-0019392-g003">Figure 3a</xref>)]. No
significant difference in insulin patterns as a function of time and treatment
between OGTT and GH&#x0002b;OGTT could be recorded (ANOVA,
p&#x0200a;=&#x0200a;0.51). Likewise, we did not observe a difference in
AUC<sub>insulin</sub> ((pmolxl<sup>&#x02212;1</sup>xmin<sup>&#x02212;1</sup>)
between OGTT and OGTT&#x0002b;GH [24908&#x000b1;4769 (OGTT) vs.
25523&#x000b1;4633 (OGTT&#x0002b;GH) (p&#x0200a;=&#x0200a;0.843)]. This
suggests that the muscles were stimulated by equal amounts of insulin in the two
situations.</p><fig id="pone-0019392-g003" position="float"><label>Figure 3</label><caption><title>Hormones and metabolites.</title><p>(A) Serum levels of insulin, no significant difference between OGTT and
GH&#x0002b;OGTT could be recorded using ANOVA repeated measurements
(p&#x0200a;=&#x0200a;0.51) or AUC<sub>insulin</sub>
(p&#x0200a;=&#x0200a;0.84). (B) Growth Hormone, (C) FFA, the degree
of FFA suppression was identical throughout the first 120&#x02005;min
between OGTT and GH &#x0002b; OGTT but the assessed the presence of GH
after 120&#x02005;min caused a reversal of the insulin suppression of
lipolysis which made AUC<sub>FFA</sub> differ significantly. Black
circles&#x0200a;=&#x0200a;OGTT &#x0002b; GH, white
circles&#x0200a;=&#x0200a;OGTT, black
triangles&#x0200a;=&#x0200a;GH. Data are presented as mean &#x000b1;
SE.</p></caption><graphic xlink:href="pone.0019392.g003"/></fig><p>The GH bolus yielded serum GH peak values after 10&#x02005;min without any impact
of a concomitant OGTT (p&#x0200a;=&#x0200a;0.81) (<xref ref-type="fig" rid="pone-0019392-g003">Figure 3b</xref>). Likewise, a comparable log-linear
decline in serum GH levels was recorded when comparing GH and GH&#x0002b;OGTT.</p><p>GH induced a &#x02248;60&#x00025; increase in serum FFA levels after 150&#x02005;min,
which was followed by a gradual decline towards baseline levels after
3&#x02005;hours (<xref ref-type="fig" rid="pone-0019392-g003">Figure 3c</xref>).
This lipolytic effect of GH was suppressed by the concomitant OGTT as
characterized by a &#x02248;85&#x00025; suppression after 120&#x02005;min and a
subsequent increase towards baseline levels after 3&#x02005;hours. As expected,
OGTT alone induced a pronounced &#x02248;90&#x00025; decrease in serum FFA levels
after 120&#x02005;min followed by a minor increase after 3&#x02005;hours to a
level still &#x02248;50&#x00025; lower than baseline. The degree of FFA suppression
was identical throughout the first 120&#x02005;min between OGTT and GH&#x0002b;OGTT
assessed by AUC<sub>FFA</sub> (p&#x0200a;=&#x0200a;0.083), however the
presence of GH after 120&#x02005;min caused a reversal of the insulin suppression
of lipolysis which made AUC<sub>FFA</sub> differ significantly
(p&#x0200a;=&#x0200a;0.026).</p></sec><sec id="s3c"><title>Stat5</title><p>GH induced a significant 17.5-fold increase in pSTAT5 (AU) after 30&#x02005;min
compared to baseline. At 60&#x02005;min the increase was 16- fold and at
120&#x02005;min 3- fold, still significantly increased compared to baseline
[87&#x000b1;16 (baseline) <italic>vs.</italic> 1513&#x000b1;415
(30&#x02005;min) (p&#x0200a;=&#x0200a;0.014); <italic>vs.</italic>
1412&#x000b1;254 (60&#x02005;min) (p&#x0200a;=&#x0200a;0.002);
<italic>vs.</italic> 275&#x000b1;65 (120&#x02005;min.)
(p&#x0200a;=&#x0200a;0.027)]. The same pattern was recorded when GH
was combined with OGTT (<xref ref-type="fig" rid="pone-0019392-g004">Figure 4a
and 4b</xref>). ANOVA for repeated measurements showed no significant
difference in pSTAT5 between GH and GH&#x0002b;OGTT
(p&#x0200a;=&#x0200a;0.64). The OGTT alone did not impact pSTAT5 (<xref ref-type="fig" rid="pone-0019392-g004">Figure 4a</xref>). We did not detect
any differences in total STAT5 expression as a function of either time or
treatment. To summarize, GH induced phosphorylation of STAT5 independently of
the OGTT.</p><fig id="pone-0019392-g004" position="float"><label>Figure 4</label><caption><title>Western blot data.</title><p>(A) Western blots illustrating comparable levels of phosphorylated
insulin signaling proteins (PAS, Aktser<sup>473</sup>,
Aktthr<sup>308</sup>, P38, pSTAT5, total STAT5 and total Akt).
Arrows indicate exposure. Effects of a GH bolus (0.5&#x02005;mg) and/or
an OGTT (75&#x02005;g) on phosphorylation of (B) STAT5. GH induced
phosphorylation of STAT5 independently of the OGTT (C)
Aktser<sup>473</sup>, (D) Aktthr<sup>308</sup>, (E) AS160, and (F)
P38. Black circles&#x0200a;=&#x0200a;OGTT &#x0002b; GH, white
circles&#x0200a;=&#x0200a;OGTT, black
triangles&#x0200a;=&#x0200a;GH. Data are presented as mean &#x000b1;
SE.</p></caption><graphic xlink:href="pone.0019392.g004"/></fig></sec><sec id="s3d"><title>Akt</title><p>The OGTT induced a significant increase in phosphorylation of Akt at
ser<sup>473</sup> and thr<sup>308</sup> (AU), which was detectable at
30&#x02005;min., 60&#x02005;min and 120&#x02005;min compared to baseline (<xref ref-type="fig" rid="pone-0019392-g004">Figure 4a, 4c, and 4d</xref>). A
similar pattern was recorded when OGTT was combined with GH exposure, although
the most pronounced increase in phosphorylation of Akt at ser<sup>473</sup>
occurred after 60&#x02005;min rather than 30&#x02005;min and phosphorylation of
Akt at thr<sup>308</sup> was significantly lower at
t&#x0200a;=&#x0200a;30&#x02005;min (p&#x0200a;=&#x0200a;0.049) and at
t&#x0200a;=&#x0200a;60&#x02005;min (p&#x0200a;=&#x0200a;0.03). By
contrast GH alone did not induce significant changes in phosphorylation of Akt
at either site. Using ANOVA for repeated measurements we found no statistical
significant difference between the two curves (OGTT and OGTT&#x0002b;GH) for either
Aktser<sup>473</sup> (p&#x0200a;=&#x0200a;0.56) or Aktthr<sup>308</sup>
(p&#x0200a;=&#x0200a;0.15). Phosphorylation of Akt at both
ser<sup>473</sup> and thr<sup>308</sup> was positively correlated to insulin
levels (p&#x0003c;0.001).We did not detect any changes in total Akt protein
expression as a function of either time or treatment.</p></sec><sec id="s3e"><title>As160 (tbc1d4) And P38</title><p>Baseline PAS phosphorylation of AS160 using the phospho-Akt substrate antibody
was comparable on all study days. OGTT alone induced a significant increase in
AS160 PAS phosphorylation (AU) after 30&#x02005;min [117&#x000b1;13
(baseline) <italic>vs.</italic> 180&#x000b1;22 (30&#x02005;min),
p&#x0200a;=&#x0200a;0.013], which was followed by non significant
elevated levels at 60 and 120&#x02005;min compared to baseline (<xref ref-type="fig" rid="pone-0019392-g004">Figure 4a, 4e</xref>). OGTT&#x0002b;GH
induced a more pronounced increase in PAS phosphorylation of AS160 (AU) which
was significant at 30&#x02005;min, 60&#x02005;min, and 120&#x02005;min compared to
baseline (OGTT&#x0002b;GH: 94&#x000b1;14 (baseline) <italic>vs.</italic>
191&#x000b1;29 (AU) (t&#x0200a;=&#x0200a;30&#x02005;min)
(p&#x0200a;=&#x0200a;0.014) <italic>vs.</italic> 230&#x000b1;36
(t&#x0200a;=&#x0200a;60&#x02005;min) (p&#x0200a;=&#x0200a;0.011)
<italic>vs.</italic> 240&#x000b1;40 (t&#x0200a;=&#x0200a;120&#x02005;min)
(p&#x0200a;=&#x0200a;0.007). ANOVA showed no significant difference between
OGTT and GH&#x0002b;OGTT (p&#x0200a;=&#x0200a;0.39). GH exposure alone induced
a decrease in PAS phosphorylation of AS160 after 60&#x02005;min.
[88&#x000b1;13 (baseline) vs. 66&#x000b1;11 (60&#x02005;min),
p&#x0200a;=&#x0200a;0.049], followed by a return to baseline levels
(<xref ref-type="fig" rid="pone-0019392-g004">Figure 4d</xref>). There was a
positive correlation between AS160 PAS phosphorylation and insulin
(r&#x0200a;=&#x0200a;0.86, p&#x0003c;0.000). As regards P38 no significant
changes were recorded with time in either experiment (<xref ref-type="fig" rid="pone-0019392-g004">Figure 4f</xref>).</p></sec><sec id="s3f"><title>Igf-I And Socs1&#x02013;3 Mrna Expression</title><p>Muscle biopsies taken at 0&#x02005;min and 120&#x02005;min were used for the
analysis of IGF-I and SOCS1&#x02013;3 mRNA expression. No significant increase in
the expression of IGF-I mRNA was observed in any of the experiments (<xref ref-type="table" rid="pone.0019392-t01">Table 1</xref>). By contrast, GH
alone significantly increased the expression of SOCS-2 mRNA (AU)
(p&#x0200a;=&#x0200a;0.008), and SOCS-3 mRNA (AU)
(p&#x0200a;=&#x0200a;0.005] compared to baseline. GH &#x0002b; OGTT
significantly increased the expression of SOCS-1 mRNA (AU)
(p&#x0200a;=&#x0200a;0.03), SOCS-2 mRNA (AU)
(p&#x0200a;=&#x0200a;0.015), and SOCS-3 mRNA (AU)
(p&#x0200a;=&#x0200a;0.038) compared to baseline. There was no significant
expression of SOCS1&#x02013;3 mRNA when oral glucose was given alone.</p><table-wrap id="pone.0019392-t01" position="float"><label>Table 1</label><caption><title>IGF-1 and SOCS 1&#x02013;3 mRNA.</title></caption><alternatives><graphic id="pone-0019392-t001-1" xlink:href="pone.0019392.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">mRNA</td><td align="left" rowspan="1" colspan="1">Units</td><td align="left" rowspan="1" colspan="1">Event</td><td align="left" rowspan="1" colspan="1">Time/min</td><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">(25&#x00025;;75&#x00025;)</td><td align="left" rowspan="1" colspan="1">Test</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>IGF-I</bold>
</td><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2.41</td><td align="left" rowspan="1" colspan="1">(0.99;11.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">(0.16;9.88)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.11</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">7.50</td><td align="left" rowspan="1" colspan="1">(2.05;15.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">6.26</td><td align="left" rowspan="1" colspan="1">(2.38;13.3)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.38</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">10.5</td><td align="left" rowspan="1" colspan="1">(2.30;25.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">12.4</td><td align="left" rowspan="1" colspan="1">(3.02;28.3)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOCS-1</bold>
</td><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">(0.37;1.66)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">(0.30;1.52)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">(0.12;1.21)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">1.79</td><td align="left" rowspan="1" colspan="1">(0.55;14.9)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.13</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">(0.24;0.86)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">2.71</td><td align="left" rowspan="1" colspan="1">(1.16;3.34)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.03&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOCS-2</bold>
</td><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">(0.50;1.50)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">(0.31;1.98)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.56</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">(0.43;1.73)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">3.07</td><td align="left" rowspan="1" colspan="1">(1.75;3.97)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.01&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1.31</td><td align="left" rowspan="1" colspan="1">(0.39;2.20)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">5.26</td><td align="left" rowspan="1" colspan="1">(2.29;15.2)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.02&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOCS-3</bold>
</td><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">(0.65;0.99)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">2.76</td><td align="left" rowspan="1" colspan="1">(0.51;3.10)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.22</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">(0.52;1.25)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">4.41</td><td align="left" rowspan="1" colspan="1">(2.02;5.89)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.01&#x0002a;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">(0.59;3.87)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AU</td><td align="left" rowspan="1" colspan="1">OGTT&#x0002b;GH</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">4.67</td><td align="left" rowspan="1" colspan="1">(2.91;15.3)</td><td align="left" rowspan="1" colspan="1">P&#x0200a;=&#x0200a;0.04&#x0002a;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>P-value after Wilcoxon rank sum test.</p></fn><fn id="nt102"><label/><p>GH, growth hormone; OGTT,oral glucose tolerance test; AU, arbitrary
unit.</p></fn><fn id="nt103"><label/><p>doi:10.1371/journal.pone.0019392.t001</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3g"><title>Correlations</title><p>To assess the impact of body composition and physical fitness on GH signaling the
percentage of total body fat (&#x00025;) and lean body mass (&#x00025;) were
correlated to peak levels of pSTAT5 and SOCS mRNA expression during the GH-only
study. Significant positive correlations were found between TBF and pSTAT5
(r&#x0200a;=&#x0200a;0.79, p&#x0200a;=&#x0200a;0.037), SOCS-2
(r&#x0200a;=&#x0200a;0.79, p&#x0200a;=&#x0200a;0.020) and
SOCS-3(r&#x0200a;=&#x0200a;0.80, p&#x0200a;=&#x0200a;0.016).
Significant negative correlations were found between LBM and pSTAT5
(r&#x0200a;=&#x0200a;&#x02212;0.79, p&#x0200a;=&#x0200a;0.033), SOCS-2
(r&#x0200a;=&#x0200a;&#x02212;0.79, p&#x0200a;=&#x0200a;0.019) and
SOCS-3(r&#x0200a;=&#x0200a;&#x02212;0.80, p&#x0200a;=&#x0200a;0.016),
and between VO<sub>2</sub>- max/kg and pSTAT5
(r&#x0200a;=&#x0200a;&#x02212;0.76, p&#x0200a;=&#x0200a;0.05) and
SOCS-3&#x02005;m RNA (r&#x0200a;=&#x0200a;&#x02212;0.73,
p&#x0200a;=&#x0200a;0.04), respectively.</p></sec></sec><sec id="s4"><title>Discussion</title><p>It is well documented that GH acutely induces insulin resistance in human skeletal
muscle in vivo <xref rid="pone.0019392-Moller2" ref-type="bibr">[2]</xref>,<xref rid="pone.0019392-Zierler1" ref-type="bibr">[19]</xref>&#x02013;<xref rid="pone.0019392-Nielsen2" ref-type="bibr">[22]</xref>, but the underlying molecular mechanisms remain unknown.
In particular - and in contrast to animal data <xref rid="pone.0019392-Dominici1" ref-type="bibr">[12]</xref> - studies in human models
have not been able to document an inhibitory effect of GH on insulin signaling
pathways in either muscle or fat <xref rid="pone.0019392-Moller1" ref-type="bibr">[1]</xref>,<xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>,<xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>,<xref rid="pone.0019392-Jessen2" ref-type="bibr">[23]</xref>,<xref rid="pone.0019392-Vestergaard1" ref-type="bibr">[24]</xref>.The human studies, however, have been conducted either in
the basal state or during a hyperinsulinemic glucose clamp, neither of which
reflects the physiological condition of a meal-induced stimulation of endogenous
insulin secretion and action. In the present study we therefore exposed healthy
subjects to an oral glucose load in the absence and presence of acute concomitant GH
exposure. This was accompanied by serial muscle biopsies to measure time course
changes in pertinent GH and insulin signaling proteins.</p><p>We observed that exposure to a single GH bolus translated into transient activation
of STAT5 signaling in skeletal muscle, which was uninfluenced by a concomitant oral
glucose load. Conversely, the oral glucose load stimulated insulin signaling in
skeletal muscle, which was modified but not abrogated by concomitant GH
exposure.</p><p>The present study confirms that phosphorylation of STAT5 in skeletal muscle is a very
robust and reproducible effect of systemic GH exposure in human subjects <xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>,<xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>,<xref rid="pone.0019392-Jessen2" ref-type="bibr">[23]</xref>,<xref rid="pone.0019392-Moller5" ref-type="bibr">[25]</xref>, and it
demonstrates for the first time that activation of STAT5 peaks 60&#x02005;min after a
GH bolus followed by a decline towards baseline levels after 120&#x02005;min. In
support of a physiological role of this response, it is noteworthy that endogenous
GH stimulated by either ghrelin <xref rid="pone.0019392-Vestergaard1" ref-type="bibr">[24]</xref> or exercise <xref rid="pone.0019392-Consitt1" ref-type="bibr">[26]</xref> also induces
pSTAT5 in human skeletal muscle in vivo. It is likely that the signaling response to
an exogenous GH bolus is influenced by the participant's pre-study exposure to
GH. Recognized determinants of GH secretion and action in human subjects include
age, gender, body composition and physical fitness <xref rid="pone.0019392-Vahl1" ref-type="bibr">[27]</xref>,<xref rid="pone.0019392-Vahl2" ref-type="bibr">[28]</xref>. We observed a positive
correlation between the participants TBF and GH signaling, whereas both LBM and
VO<sub>2</sub>- max/body weight correlated negatively with GH signaling. Fat
mass is known to be inversely related to GH secretion (also in normal weight
subjects), whereas the opposite is true for LBM and VO<sub>2</sub>- max <xref rid="pone.0019392-Vahl1" ref-type="bibr">[27]</xref>,<xref rid="pone.0019392-Vahl2" ref-type="bibr">[28]</xref>. To reconcile
these observations we speculate that pre-study GH levels may suppress GH signaling
induced by an exogenous GH bolus. This hypothesis obviously needs to be
experimentally addressed in future studies which also should account for other
determinants of GH secretion such as gender and age.</p><p>The GH-induced activation of STAT5 was unaffected by a concomitant oral glucose load,
which is in accord with observations made during a hyperinsulinemic glucose clamp
<xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>. It has
previously been reported that prolonged (8&#x02013;24&#x02005;h) but not short-term
(4&#x02005;h) insulin pretreatment inhibits GH signaling via the GHR/JAK2/STAT5B
pathway in rat hepatoma cells <xref rid="pone.0019392-Xu1" ref-type="bibr">[29]</xref>,<xref rid="pone.0019392-Xu2" ref-type="bibr">[30]</xref>. Conversely, rapid tyrosine phosphorylation of STAT5 by
insulin has been recorded in a perfused rat liver model <xref rid="pone.0019392-Chen1" ref-type="bibr">[31]</xref>. Whether these discrepancies
reflect tissue-specific or species-specific differences remain uncertain, but at
present there is no evidence to support that insulin interacts with GH signaling in
human muscle or fat in vivo.</p><p>We observed that insulin signaling proteins in human skeletal muscle in vivo are
activated in a distinct temporal pattern within 30&#x02005;min after an OGTT. The
serial measurements of insulin signaling activity during the OGTT allow examination
of temporal physiological changes that may not be detected during a glucose clamp.
Muscle glucose uptake is difficult to quantify directly during an OGTT. However it
has previously been demonstrated that glucose from an OGTT for the most part is
disposed into skeletal muscle <xref rid="pone.0019392-Katz1" ref-type="bibr">[32]</xref>. We therefore consider an OGTT an acceptable model for
studying the impact of GH on stimulated insulin signaling and glucose uptake in
skeletal muscle.</p><p>Previous studies in human in vivo models have failed to detect effects of GH, given
as either an infusion <xref rid="pone.0019392-Jessen2" ref-type="bibr">[23]</xref> or a bolus <xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>,<xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>, on insulin signaling via
IRS-1 associated PI3-kinase <xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>,<xref rid="pone.0019392-Jessen2" ref-type="bibr">[23]</xref>, serine/threonine kinase Akt <xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>,<xref rid="pone.0019392-Jorgensen1" ref-type="bibr">[14]</xref>,<xref rid="pone.0019392-Jessen2" ref-type="bibr">[23]</xref>, and Erk1 <xref rid="pone.0019392-Nielsen1" ref-type="bibr">[13]</xref>. This, together with the
present data, deviates from animal as well as <italic>in vitro</italic> studies
showing that inhibition of the IRS1-Akt pathway is a mechanism whereby GH induces
insulin resistance in skeletal muscle <xref rid="pone.0019392-Dominici1" ref-type="bibr">[12]</xref> and fat <xref rid="pone.0019392-delRincon1" ref-type="bibr">[33]</xref>. Our present data, however,
show that phosphorylation of the intermediary signaling proteins
Aktser<sup>473</sup> and Aktthr<sup>308</sup> tended to be delayed
(Aktser<sup>473</sup>) and suppressed (Aktthr<sup>308</sup>) when GH was given
in combination with OGTT, whereas further downstream phosphorylation of AS160 was
more pronounced when GH was combined with OGTT. Most agree that phosphorylation of
Aktthr<sup>308</sup> occurs prior to phosphorylation of Aktser473 and that this
is a two-step process; based on our data it is likely that GH may interact with this
process. The physiological significance, however, is unclear when considering that
the activation of AS160, which is downstream of Aktser473, was activated rather than
suppressed by GH. It remains to be studied whether the latter may reflect an
inhibitory effect of GH on insulin signaling downstream of AS160.</p><p>It is well known that GH via STAT5 stimulates SOCS expression <xref rid="pone.0019392-Ram1" ref-type="bibr">[34]</xref> and that SOCS-3 is the major
negative regulator of GH signaling <xref rid="pone.0019392-FloresMorales1" ref-type="bibr">[35]</xref>&#x02013;<xref rid="pone.0019392-Rieusset1" ref-type="bibr">[38]</xref>. Animal
studies suggest that SOCS-1 inhibits insulin-stimulated activation of the Erk1/2 and
Akt <italic>in vivo</italic>, and phosphorylation of IRS-1 by the IR <italic>in
vitro</italic>
<xref rid="pone.0019392-Mooney1" ref-type="bibr">[39]</xref>. We found
that after 2&#x02005;hours, GH induced a significant increase in the expression of
both SOCS2 and SOCS3 mRNA expression, and that GH in combination with OGTT also
induced a significant increase in SOCS1 mRNA. However, none of these changes was
associated with the phosphorylation of Akt. It is also well described that elevated
FFA levels are causally linked to insulin resistance although the underlying
mechanisms are unclear <xref rid="pone.0019392-Shulman1" ref-type="bibr">[10]</xref>,<xref rid="pone.0019392-Randle1" ref-type="bibr">[40]</xref>,<xref rid="pone.0019392-Hue1" ref-type="bibr">[41]</xref>. In accordance with this, we have previously observed
that experimental suppression of lipolysis in conjunction with GH administration in
GH-deficient adults significantly abrogates the antagonistic effects of GH on
insulin-stimulated muscle glucose uptake <xref rid="pone.0019392-Nielsen2" ref-type="bibr">[22]</xref>, and that insulin resistance
induced by short-term high dose GH administration in healthy adults is accompanied
by accumulation of fat in muscle cells <xref rid="pone.0019392-Krag1" ref-type="bibr">[42]</xref>. But in contrast to data obtained
with intralipid infusion in human subjects, we have not been able to detect
suppression of either PI 3-kinase or Akt/PKB following GH-induced insulin resistance
during a glucose clamp despite a marked elevation in circulating FFA levels <xref rid="pone.0019392-Jessen2" ref-type="bibr">[23]</xref>. In the present
study the lipolytic effect of GH was blunted by the concomitant OGTT, although the
degree of suppression was significantly less as compared to OGTT alone (<xref ref-type="fig" rid="pone-0019392-g003">Figure 3c</xref>). Measurement of
intramyocellular lipid content would have strengthened the study but would have
required a separate preparation and thus much larger biopsies.</p><sec id="s4a"><title>Conclusions</title><p>We conclude that a physiological GH bolus activates STAT5 signaling pathways
acutely in skeletal muscle irrespective of ambient circulating glucose and
insulin levels. The acute antagonistic effects of GH on glucose-stimulated
insulin action were accompanied by a moderate suppression of Akt activation,
whereas the expression of the more downstream signaling protein AS160 was
amplified rather than suppressed by GH. Our model provides a viable tool to
study GH and insulin action in human target tissues in vivo.</p></sec></sec></body><back><ack><p>K.N. Rasmussen, H.F. Petersen and E. S. Hornemann are acknowledged for excellent
technical assistance.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have the following competing interests: JOLJ has received
unrestricted research grant and lecture fee from Pfizer Inc. The study was
funded by Novo Nordisk. There are no patents, products in development or
marketed products to declare. This does not alter the authors&#x02019; adherence to all
the PLoS ONE policies on sharing data and materials, as detailed online in the
guide for authors. The other authors have declared that no competing interests
exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was sponsored by Novo Nordisk via an unrestricted research grant. The
funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0019392-Moller1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name></person-group><article-title>Effects of growth hormone on glucose, lipid, and protein
metabolism in human subjects.</article-title><source>Endocr Rev</source><year>2009</year><volume>30</volume><fpage>152</fpage><lpage>177</lpage><comment>er.2008-0027 [pii];10.1210/er.2008-0027
[doi]</comment><pub-id pub-id-type="pmid">19240267</pub-id></element-citation></ref><ref id="pone.0019392-Moller2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>N</given-names></name></person-group><article-title>Effects of growth hormone on insulin sensitivity and forearm
metabolism in normal man.</article-title><source>Diabetologia</source><year>1989</year><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">2656349</pub-id></element-citation></ref><ref id="pone.0019392-Moller3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Moller</surname><given-names>J</given-names></name><name><surname>Christiansen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of a growth hormone pulse on total and forearm substrate
fluxes in humans.</article-title><source>Am J Physiol</source><year>1990</year><volume>258</volume><fpage>E86</fpage><lpage>E91</lpage><pub-id pub-id-type="pmid">2405702</pub-id></element-citation></ref><ref id="pone.0019392-Norrelund1"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norrelund</surname><given-names>H</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Nair</surname><given-names>KS</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name></person-group><article-title>Continuation of growth hormone (GH) substitution during fasting
in GH-deficient patients decreases urea excretion and conserves protein
synthesis.</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>3120</fpage><lpage>3129</lpage><pub-id pub-id-type="pmid">11443176</pub-id></element-citation></ref><ref id="pone.0019392-Norrelund2"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norrelund</surname><given-names>H</given-names></name><name><surname>Nair</surname><given-names>KS</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name></person-group><article-title>The protein-retaining effects of growth hormone during fasting
involve inhibition of muscle-protein breakdown.</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">11147801</pub-id></element-citation></ref><ref id="pone.0019392-Norrelund3"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norrelund</surname><given-names>H</given-names></name><name><surname>Djurhuus</surname><given-names>C</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Nair</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Effects of GH on urea, glucose and lipid metabolism, and insulin
sensitivity during fasting in GH-deficient patients.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2003</year><volume>285</volume><fpage>E737</fpage><lpage>E743</lpage><comment>10.1152/ajpendo.00092.2003 [doi];00092.2003
[pii]</comment><pub-id pub-id-type="pmid">12799313</pub-id></element-citation></ref><ref id="pone.0019392-Moller4"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Joorgensen</surname><given-names>JO</given-names></name><name><surname>Astrup</surname><given-names>J</given-names></name><name><surname>Bak</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Basal- and insulin-stimulated substrate metabolism in patients
with active acromegaly before and after adenomectomy.</article-title><source>J Clin Endocrinol Metab</source><year>1992</year><volume>74</volume><fpage>1012</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">1569148</pub-id></element-citation></ref><ref id="pone.0019392-Sonksen1"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonksen</surname><given-names>PH</given-names></name><name><surname>Greenwood</surname><given-names>FC</given-names></name><name><surname>Ellis</surname><given-names>JP</given-names></name><name><surname>Lowy</surname><given-names>C</given-names></name><name><surname>Rutherford</surname><given-names>A</given-names></name><etal/></person-group><article-title>Changes of carbohydrate tolerance in acromegaly with progress of
the disease and in response to treatment.</article-title><source>J Clin Endocrinol Metab</source><year>1967</year><volume>27</volume><fpage>1418</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">6057823</pub-id></element-citation></ref><ref id="pone.0019392-Sakamoto1"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Holman</surname><given-names>GD</given-names></name></person-group><article-title>Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of
GLUT4 traffic.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2008</year><volume>295</volume><fpage>E29</fpage><lpage>E37</lpage><comment>90331.2008 [pii];10.1152/ajpendo.90331.2008
[doi]</comment><pub-id pub-id-type="pmid">18477703</pub-id></element-citation></ref><ref id="pone.0019392-Shulman1"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Unraveling the cellular mechanism of insulin resistance in
humans: new insights from magnetic resonance spectroscopy.</article-title><source>Physiology (Bethesda)</source><year>2004</year><volume>19</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">15304632</pub-id></element-citation></ref><ref id="pone.0019392-Lanning1"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanning</surname><given-names>N</given-names></name><name><surname>Carter-Su</surname><given-names>C</given-names></name></person-group><article-title>Recent advances in growth hormone signaling.</article-title><source>Rev Endocr Metab Disord</source><year>2006</year></element-citation></ref><ref id="pone.0019392-Dominici1"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominici</surname><given-names>FP</given-names></name><name><surname>Argentino</surname><given-names>DP</given-names></name><name><surname>Munoz</surname><given-names>MC</given-names></name><name><surname>Miquet</surname><given-names>JG</given-names></name><name><surname>Sotelo</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Influence of the crosstalk between growth hormone and insulin
signalling on the modulation of insulin sensitivity.</article-title><source>Growth Horm IGF Res</source><year>2005</year><volume>15</volume><fpage>324</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">16112592</pub-id></element-citation></ref><ref id="pone.0019392-Nielsen1"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>C</given-names></name><name><surname>Gormsen</surname><given-names>LC</given-names></name><name><surname>Jessen</surname><given-names>N</given-names></name><name><surname>Pedersen</surname><given-names>SB</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><etal/></person-group><article-title>Growth hormone signaling in vivo in human muscle and adipose
tissue: impact of insulin, substrate background, and growth hormone receptor
blockade.</article-title><source>J Clin Endocrinol Metab</source><year>2008</year><volume>93</volume><fpage>2842</fpage><lpage>2850</lpage><pub-id pub-id-type="pmid">18460563</pub-id></element-citation></ref><ref id="pone.0019392-Jorgensen1"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Jessen</surname><given-names>N</given-names></name><name><surname>Pedersen</surname><given-names>SB</given-names></name><name><surname>Vestergaard</surname><given-names>E</given-names></name><name><surname>Gormsen</surname><given-names>L</given-names></name><etal/></person-group><article-title>GH receptor signaling in skeletal muscle and adipose tissue in
human subjects following exposure to an intravenous GH
bolus.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2006</year><volume>291</volume><fpage>E899</fpage><lpage>E905</lpage><pub-id pub-id-type="pmid">16757551</pub-id></element-citation></ref><ref id="pone.0019392-Wojtaszewski1"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojtaszewski</surname><given-names>JF</given-names></name><name><surname>Hansen</surname><given-names>BF</given-names></name><name><surname>Urso</surname><given-names>B</given-names></name><name><surname>Richter</surname><given-names>EA</given-names></name></person-group><article-title>Wortmannin inhibits both insulin- and contraction-stimulated
glucose uptake and transport in rat skeletal muscle.</article-title><source>J Appl Physiol</source><year>1996</year><volume>81</volume><fpage>1501</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">8904560</pub-id></element-citation></ref><ref id="pone.0019392-Jessen1"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname><given-names>N</given-names></name><name><surname>Selmer</surname><given-names>BE</given-names></name><name><surname>Pold</surname><given-names>R</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Lund</surname><given-names>S</given-names></name></person-group><article-title>A novel insulin sensitizer (S15511) enhances insulin-stimulated
glucose uptake in rat skeletal muscles.</article-title><source>Horm Metab Res</source><year>2008</year><volume>40</volume><fpage>269</fpage><lpage>275</lpage><comment>10.1055/s-2007-1022546 [doi]</comment><pub-id pub-id-type="pmid">18548386</pub-id></element-citation></ref><ref id="pone.0019392-Treebak1"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treebak</surname><given-names>JT</given-names></name><name><surname>Birk</surname><given-names>JB</given-names></name><name><surname>Rose</surname><given-names>AJ</given-names></name><name><surname>Kiens</surname><given-names>B</given-names></name><name><surname>Richter</surname><given-names>EA</given-names></name><etal/></person-group><article-title>AS160 phosphorylation is associated with activation of
alpha2beta2gamma1- but not alpha2beta2gamma3-AMPK trimeric complex in
skeletal muscle during exercise in humans.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2007</year><volume>292</volume><fpage>E715</fpage><lpage>E722</lpage><comment>00380.2006 [pii];10.1152/ajpendo.00380.2006
[doi]</comment><pub-id pub-id-type="pmid">17077344</pub-id></element-citation></ref><ref id="pone.0019392-Hojlund1"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hojlund</surname><given-names>K</given-names></name><name><surname>Glintborg</surname><given-names>D</given-names></name><name><surname>Andersen</surname><given-names>NR</given-names></name><name><surname>Birk</surname><given-names>JB</given-names></name><name><surname>Treebak</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Impaired insulin-stimulated phosphorylation of Akt and AS160 in
skeletal muscle of women with polycystic ovary syndrome is reversed by
pioglitazone treatment.</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>357</fpage><lpage>366</lpage><comment>db07-0706 [pii];10.2337/db07-0706 [doi]</comment><pub-id pub-id-type="pmid">17977950</pub-id></element-citation></ref><ref id="pone.0019392-Zierler1"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zierler</surname><given-names>KL</given-names></name><name><surname>Rabinowitz</surname><given-names>D</given-names></name></person-group><article-title>Roles of insulin and growth hormone, based on studies of forearm
metabolism in man.</article-title><source>Medicine (Baltimore)</source><year>1963</year><volume>42</volume><fpage>385</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">14085535</pub-id></element-citation></ref><ref id="pone.0019392-Bak1"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bak</surname><given-names>JF</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name></person-group><article-title>Effects of growth hormone on fuel utilization and muscle glycogen
synthase activity in normal humans.</article-title><source>Am J Physiol</source><year>1991</year><volume>260</volume><fpage>E736</fpage><lpage>E742</lpage><pub-id pub-id-type="pmid">1903598</pub-id></element-citation></ref><ref id="pone.0019392-Jorgensen2"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Moller</surname><given-names>J</given-names></name><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Marked effects of sustained low growth hormone (GH) levels on
day-to-day fuel metabolism: studies in GH-deficient patients and healthy
untreated subjects.</article-title><source>J Clin Endocrinol Metab</source><year>1993</year><volume>77</volume><fpage>1589</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">8263146</pub-id></element-citation></ref><ref id="pone.0019392-Nielsen2"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name></person-group><article-title>Pharmacological antilipolysis restores insulin sensitivity during
growth hormone exposure.</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>2301</fpage><lpage>2308</lpage><pub-id pub-id-type="pmid">11574412</pub-id></element-citation></ref><ref id="pone.0019392-Jessen2"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname><given-names>N</given-names></name><name><surname>Djurhuus</surname><given-names>CB</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Jensen</surname><given-names>LS</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><etal/></person-group><article-title>Evidence against a role for insulin-signaling proteins PI
3-kinase and Akt in insulin resistance in human skeletal muscle induced by
short-term GH infusion.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><fpage>E194</fpage><lpage>E199</lpage><pub-id pub-id-type="pmid">15339744</pub-id></element-citation></ref><ref id="pone.0019392-Vestergaard1"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestergaard</surname><given-names>ET</given-names></name><name><surname>Gormsen</surname><given-names>LC</given-names></name><name><surname>Jessen</surname><given-names>N</given-names></name><name><surname>Lund</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Ghrelin infusion in humans induces acute insulin resistance and
lipolysis independent of growth hormone signaling.</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>3205</fpage><lpage>3210</lpage><comment>db08-0025 [pii];10.2337/db08-0025 [doi]</comment><pub-id pub-id-type="pmid">18776138</pub-id></element-citation></ref><ref id="pone.0019392-Moller5"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>L</given-names></name><name><surname>Dalman</surname><given-names>L</given-names></name><name><surname>Norrelund</surname><given-names>H</given-names></name><name><surname>Billestrup</surname><given-names>N</given-names></name><name><surname>Frystyk</surname><given-names>J</given-names></name><etal/></person-group><article-title>Impact of fasting on growth hormone signaling and action in
muscle and fat.</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>965</fpage><lpage>972</lpage><comment>jc.2008-1385 [pii];10.1210/jc.2008-1385
[doi]</comment><pub-id pub-id-type="pmid">19066303</pub-id></element-citation></ref><ref id="pone.0019392-Consitt1"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consitt</surname><given-names>LA</given-names></name><name><surname>Wideman</surname><given-names>L</given-names></name><name><surname>Hickey</surname><given-names>MS</given-names></name><name><surname>Morrison</surname><given-names>RF</given-names></name></person-group><article-title>Phosphorylation of the JAK2-STAT5 pathway in response to acute
aerobic exercise.</article-title><source>Medicine and Science in Sports and Exercise</source><year>2008</year><volume>40</volume><fpage>1031</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">18461004</pub-id></element-citation></ref><ref id="pone.0019392-Vahl1"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahl</surname><given-names>N</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Skjaerbaek</surname><given-names>C</given-names></name><name><surname>Veldhuis</surname><given-names>JD</given-names></name><name><surname>Orskov</surname><given-names>H</given-names></name><etal/></person-group><article-title>Abdominal adiposity rather than age and sex predicts mass and
regularity of GH secretion in healthy adults.</article-title><source>Am J Physiol</source><year>1997</year><volume>272</volume><fpage>E1108</fpage><lpage>E1116</lpage><pub-id pub-id-type="pmid">9227458</pub-id></element-citation></ref><ref id="pone.0019392-Vahl2"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahl</surname><given-names>N</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Lauritzen</surname><given-names>T</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name></person-group><article-title>Metabolic effects and pharmacokinetics of a growth hormone pulse
in healthy adults: relation to age, sex, and body
composition.</article-title><source>J Clin Endocrinol Metab</source><year>1997</year><volume>82</volume><fpage>3612</fpage><lpage>3618</lpage><pub-id pub-id-type="pmid">9360515</pub-id></element-citation></ref><ref id="pone.0019392-Xu1"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Keeton</surname><given-names>AB</given-names></name><name><surname>Franklin</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Venable</surname><given-names>DY</given-names></name><etal/></person-group><article-title>Insulin enhances growth hormone induction of the MEK/ERK
signaling pathway.</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>982</fpage><lpage>992</lpage><comment>M505484200 [pii];10.1074/jbc.M505484200
[doi]</comment><pub-id pub-id-type="pmid">16272159</pub-id></element-citation></ref><ref id="pone.0019392-Xu2"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Messina</surname><given-names>JL</given-names></name></person-group><article-title>Crosstalk between growth hormone and insulin
signaling.</article-title><source>Vitam Horm</source><year>2009</year><volume>80</volume><fpage>125</fpage><lpage>153</lpage><comment>S0083-6729(08)00606-7 [pii];10.1016/S0083-6729(08)00606-7
[doi]</comment><pub-id pub-id-type="pmid">19251037</pub-id></element-citation></ref><ref id="pone.0019392-Chen1"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sadowski</surname><given-names>HB</given-names></name><name><surname>Kohanski</surname><given-names>RA</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name></person-group><article-title>Stat5 is a physiological substrate of the insulin
receptor.</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>2295</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">9122188</pub-id></element-citation></ref><ref id="pone.0019392-Katz1"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>LD</given-names></name><name><surname>Glickman</surname><given-names>MG</given-names></name><name><surname>Rapoport</surname><given-names>S</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Defronzo</surname><given-names>RA</given-names></name></person-group><article-title>Splanchnic and peripheral disposal of oral glucose in
man.</article-title><source>Diabetes</source><year>1983</year><volume>32</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">6862113</pub-id></element-citation></ref><ref id="pone.0019392-delRincon1"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Rincon</surname><given-names>JP</given-names></name><name><surname>Iida</surname><given-names>K</given-names></name><name><surname>Gaylinn</surname><given-names>BD</given-names></name><name><surname>McCurdy</surname><given-names>CE</given-names></name><name><surname>Leitner</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Growth hormone regulation of p85alpha expression and
phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth
hormone-mediated insulin resistance.</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>1638</fpage><lpage>1646</lpage><comment>db06-0299 [pii];10.2337/db06-0299 [doi]</comment><pub-id pub-id-type="pmid">17363744</pub-id></element-citation></ref><ref id="pone.0019392-Ram1"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram</surname><given-names>PA</given-names></name><name><surname>Waxman</surname><given-names>DJ</given-names></name></person-group><article-title>SOCS/CIS protein inhibition of growth hormone-stimulated STAT5
signaling by multiple mechanisms.</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>35553</fpage><lpage>35561</lpage><pub-id pub-id-type="pmid">10585430</pub-id></element-citation></ref><ref id="pone.0019392-FloresMorales1"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Morales</surname><given-names>A</given-names></name><name><surname>Greenhalgh</surname><given-names>CJ</given-names></name><name><surname>Norstedt</surname><given-names>G</given-names></name><name><surname>Rico-Bautista</surname><given-names>E</given-names></name></person-group><article-title>Negative regulation of growth hormone receptor
signaling.</article-title><source>Mol Endocrinol</source><year>2006</year><volume>20</volume><fpage>241</fpage><lpage>253</lpage><comment>me.2005-0170 [pii];10.1210/me.2005-0170
[doi]</comment><pub-id pub-id-type="pmid">16037128</pub-id></element-citation></ref><ref id="pone.0019392-Davey1"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>HW</given-names></name><name><surname>McLachlan</surname><given-names>MJ</given-names></name><name><surname>Wilkins</surname><given-names>RJ</given-names></name><name><surname>Hilton</surname><given-names>DJ</given-names></name><name><surname>Adams</surname><given-names>TE</given-names></name></person-group><article-title>STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3
mRNA in the liver.</article-title><source>Mol Cell Endocrinol</source><year>1999</year><volume>158</volume><fpage>111</fpage><lpage>116</lpage><comment>S0303-7207(99)00175-6 [pii]</comment><pub-id pub-id-type="pmid">10630411</pub-id></element-citation></ref><ref id="pone.0019392-Ridderstrale1"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridderstrale</surname><given-names>M</given-names></name><name><surname>Amstrup</surname><given-names>J</given-names></name><name><surname>Hilton</surname><given-names>DJ</given-names></name><name><surname>Billestrup</surname><given-names>N</given-names></name><name><surname>Tornqvist</surname><given-names>H</given-names></name></person-group><article-title>SOCS-3 is involved in the downregulation of the acute
insulin-like effects of growth hormone in rat adipocytes by inhibition of
Jak2/IRS-1 signaling.</article-title><source>Horm Metab Res</source><year>2003</year><volume>35</volume><fpage>169</fpage><lpage>177</lpage><comment>10.1055/s-2003-39077 [doi]</comment><pub-id pub-id-type="pmid">12734778</pub-id></element-citation></ref><ref id="pone.0019392-Rieusset1"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieusset</surname><given-names>J</given-names></name><name><surname>Bouzakri</surname><given-names>K</given-names></name><name><surname>Chevillotte</surname><given-names>E</given-names></name><name><surname>Ricard</surname><given-names>N</given-names></name><name><surname>Jacquet</surname><given-names>D</given-names></name><etal/></person-group><article-title>Suppressor of cytokine signaling 3 expression and insulin
resistance in skeletal muscle of obese and type 2 diabetic
patients.</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>2232</fpage><lpage>2241</lpage><comment>53/9/2232 [pii]</comment><pub-id pub-id-type="pmid">15331532</pub-id></element-citation></ref><ref id="pone.0019392-Mooney1"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mooney</surname><given-names>RA</given-names></name><name><surname>Senn</surname><given-names>J</given-names></name><name><surname>Cameron</surname><given-names>S</given-names></name><name><surname>Inamdar</surname><given-names>N</given-names></name><name><surname>Boivin</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Suppressors of cytokine signaling-1 and -6 associate with and
inhibit the insulin receptor. A potential mechanism for cytokine-mediated
insulin resistance.</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>25889</fpage><lpage>25893</lpage><pub-id pub-id-type="pmid">11342531</pub-id></element-citation></ref><ref id="pone.0019392-Randle1"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randle</surname><given-names>PJ</given-names></name><name><surname>Garland</surname><given-names>PB</given-names></name><name><surname>Hales</surname><given-names>CN</given-names></name><name><surname>Newsholme</surname><given-names>EA</given-names></name></person-group><article-title>The glucose fatty-acid cycle. Its role in insulin sensitivity and
the metabolic disturbances of diabetes mellitus.</article-title><source>Lancet</source><year>1963</year><volume>1</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">13990765</pub-id></element-citation></ref><ref id="pone.0019392-Hue1"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hue</surname><given-names>L</given-names></name><name><surname>Taegtmeyer</surname><given-names>H</given-names></name></person-group><article-title>The Randle cycle revisited: a new head for an old
hat.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2009</year><volume>297</volume><fpage>E578</fpage><lpage>E591</lpage><comment>00093.2009 [pii];10.1152/ajpendo.00093.2009
[doi]</comment><pub-id pub-id-type="pmid">19531645</pub-id></element-citation></ref><ref id="pone.0019392-Krag1"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krag</surname><given-names>MB</given-names></name><name><surname>Gormsen</surname><given-names>LC</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Jensen</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Growth hormone-induced insulin resistance is associated with
increased intramyocellular triglyceride content but unaltered
VLDL-triglyceride kinetics.</article-title><source>Am J Physiol Endocrinol Metab</source><year>2007</year><volume>292</volume><fpage>E920</fpage><lpage>E927</lpage><comment>00374.2006 [pii];10.1152/ajpendo.00374.2006
[doi]</comment><pub-id pub-id-type="pmid">17132823</pub-id></element-citation></ref></ref-list></back></article>